MedPath
FDA Approval

Lamivudine and Zidovudine

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
May 11, 2022
Labeling Type
Human Prescription Drug Label
Lamivudine(150 mg in 1 1)
Zidovudine(300 mg in 1 1)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Aurobindo Pharma Limited

Aurobindo Pharma Limited

650381903

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Lamivudine and Zidovudine

Product Details

NDC Product Code
65862-036
Application Number
ANDA077558
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
May 11, 2022
Code: 2T8Q726O95Class: ACTIBQuantity: 150 mg in 1 1
Code: 4B9XT59T7SClass: ACTIBQuantity: 300 mg in 1 1
HYPROMELLOSE 2910 (6 MPA.S)Inactive
Code: 0WZ8WG20P6Class: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4Class: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30Class: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61UClass: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
POLYETHYLENE GLYCOL 400Inactive
Code: B697894SGQClass: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2Class: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JPClass: IACT
© Copyright 2025. All Rights Reserved by MedPath